Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038561 | 0.99 | GSK3B (0.62) | GSK3BCYP2C9 | |
| SCHEMBL5096032 | 0.96 | GSK3B (0.61) | GSK3B | |
| SCHEMBL5105229 | 0.96 | GSK3B (0.61) | GSK3B | |
| SCHEMBL5045497 | 0.95 | GSK3B (0.62) | GSK3B | |
| SCHEMBL2403941 | 0.95 | GSK3B (0.62) | GSK3B | |
| SCHEMBL5104876 | 0.95 | GSK3B (0.62) | GSK3B | |
| SCHEMBL5041737 | 0.94 | GSK3B (0.64) | GSK3B | |
| SCHEMBL5561339 | 0.94 | GSK3B (0.64) | GSK3B | |
| SCHEMBL5104968 | 0.93 | GSK3B (0.69) | GSK3B | |
| SCHEMBL5098141 | 0.93 | GSK3B (0.69) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778657-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | claimed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | claimed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | claimed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | claimed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | claimed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1276738-B1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2007-12-12 | — | — | EP | disclosed |
| EP-1751141-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | Aventis Pharma S.A. (FR) | 2007-02-14 | — | — | EP | disclosed |
| CN-1891220-A | Use of 2-amino-3-alkylpyrimidinone derivatives for producing medicaments | SANOFI SYNTHELABO (FR) | 2007-01-10 | — | — | CN | disclosed |
| CN-1247567-C | 2-amino-3-alkylpyrimidinone derivatives as GSK3 beta inhibitors | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | CN | disclosed |
| WO-2005111019-A1 | NOVEL PYRIDAZINONE DERIVATIVES AS INHIBITORS OF CDK2 | AVENTIS PHARMA S.A. (FR) | 2005-11-24 | — | — | WO | disclosed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | disclosed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | SANOFI (FR) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885CYP2C9 2538/4885 |
| US-20030187004-A1 | 2-Amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors | GSK3A, GSK3B, CSNK2A3 | GSK3B 2/4885CYP2C9 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.